While there is promising evidence of improved response in BRCA1/2m carriers,60,75–80 this approach is challenging due to the associated dose-limiting myelosuppression.78,79,81 The BROCADE 2 (NCT01506609),82 and BROCADE 3 (NCT02163694)83 studies, which are randomised phase II and phase III investigations, respectively, are comparing paclitaxel and carboplatin with or without the PARPi veliparib in BRCA1/2m carriers with metastatic BC. Here, BRCA1 is linked to breast cancer.